Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,550.00
-850.00 (-10.12%)
At close: Feb 6, 2026

Revenue by Product

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Immuno-cancer Drugs - Product
13.36B
Immuno-cancer Drugs - Product Growth
115.01%
Service
7.29B
Service Growth
-7.26%
Usage Fee
7.10B
Usage Fee Growth
3251.04%
Immuno-cancer Drugs - Merchandise
800.00K
Immuno-cancer Drugs - Merchandise Growth
-94.84%

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
North America
9.60B
Europe
7.37B
South Korea
6.30B
South Korea Growth
-55.92%
Asia
4.43B
South America
29.46M
Oceania
10.97M